A narrative review of nontuberculous mycobacterial pulmonary disease: microbiology, epidemiology, diagnosis, and management challenges

References

• Cook GM, Berney M, Gebhard S, et al. Physiology of mycobacteria. Adv Microb Physiol. 2009;55:81–182, 318–9. doi: 10.1016/S0065-2911(09)05502-7
   Web of Science ®Google Scholar
• Hayman J. Mycobacterium ulcerans: an infection from Jurassic time? Lancet. 1984 Nov 3;2(8410):1015–1016. doi: 10.1016/S0140-6736(84)91110-3
   PubMed Web of Science ®Google Scholar
• Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev. 2003 Jul;16(3):463–496. doi: 10.1128/CMR.16.3.463-496.2003
   PubMed Web of Science ®Google Scholar
• Brode SK, Daley CL, Marras TK. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis. 2014 Nov;18(11):1370–1377. doi: 10.5588/ijtld.14.0120
   PubMed Web of Science ®Google Scholar
• Falkinham JO. 3rd. Environmental sources of nontuberculous mycobacteria. Clin Chest Med. 2015 Mar;36(1):35–41. doi: 10.1016/j.ccm.2014.10.003
   PubMed Web of Science ®Google Scholar
• Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020 Aug 14;71(4):905–913. doi: 10.1093/cid/ciaa1125
   PubMed Web of Science ®Google Scholar
• Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010 Oct 1;182(7):977–982. doi: 10.1164/rccm.201003-0503OC
   PubMed Web of Science ®Google Scholar
• Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J Thorac Dis. 2014 Mar;6(3):210–220. doi: 10.3978/j.issn.2072-1439.2013.12.24
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367–416. doi: 10.1164/rccm.200604-571ST
   PubMed Web of Science ®Google Scholar
• LPSN. Genus Mycobacterium Sudbury, Massachusetts2023. [cited 2023 Jun 6]. Available from: https://lpsn.dsmz.de/genus/mycobacterium
   Google Scholar
• Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015 Mar;36(1):13–34. doi: 10.1016/j.ccm.2014.10.002
   PubMed Web of Science ®Google Scholar
• Yan M, Brode SK, Marras TK. The other nontuberculous mycobacteria: clinical aspects of lung disease caused by less common slowly growing nontuberculous mycobacteria species. Chest. 2023 Feb;163(2):281–291. doi: 10.1016/j.chest.2022.09.025
   PubMed Web of Science ®Google Scholar
• Jacobs JM, Stine CB, Baya AM, et al. A review of mycobacteriosis in marine fish. J Fish Dis. 2009 Feb;32(2):119–130. doi: 10.1111/j.1365-2761.2008.01016.x
   PubMed Web of Science ®Google Scholar
• Iivanainen EK, Martikainen PJ, Vaananen PK, et al. Environmental factors affecting the occurrence of mycobacteria in brook waters. Appl Environ Microbiol. 1993 Feb;59(2):398–404. doi: 10.1128/aem.59.2.398-404.1993
   PubMed Web of Science ®Google Scholar
• Amha YM, Anwar MZ, Kumaraswamy R, et al. Mycobacteria in municipal wastewater treatment and reuse: microbial diversity for screening the occurrence of clinically and environmentally relevant species in arid regions. Environ Sci Technol. 2017 Mar 7;51(5):3048–3056. doi: 10.1021/acs.est.6b05580
   PubMed Web of Science ®Google Scholar
• Thomson R, Tolson C, Sidjabat H, et al. Mycobacterium abscessus isolated from municipal water - a potential source of human infection. BMC Infect Dis. 2013 May 25;13(1):241. doi: 10.1186/1471-2334-13-241
   PubMedGoogle Scholar
• Thomson R, Tolson C, Carter R, et al. Isolation of nontuberculous mycobacteria (NTM) from household water and shower aerosols in patients with pulmonary disease caused by NTM. J Clin Microbiol. 2013 Sep;51(9):3006–3011. doi: 10.1128/JCM.00899-13
   PubMed Web of Science ®Google Scholar
• Cooksey RC, Jhung MA, Yakrus MA, et al. Multiphasic approach reveals genetic diversity of environmental and patient isolates of Mycobacterium mucogenicum and Mycobacterium phocaicum associated with an outbreak of bacteremias at a Texas hospital. Appl Environ Microbiol. 2008 Apr;74(8):2480–2487. doi: 10.1128/AEM.02476-07
   PubMed Web of Science ®Google Scholar
• Falkinham JO 3rd, Iseman MD, de Haas P, et al. Mycobacterium avium in a shower linked to pulmonary disease. J Water Health. 2008 Jun;6(2):209–213. doi: 10.2166/wh.2008.232
   PubMed Web of Science ®Google Scholar
• Lumb R, Stapledon R, Scroop A, et al. Investigation of spa pools associated with lung disorders caused by Mycobacterium avium complex in immunocompetent adults. Appl Environ Microbiol. 2004 Aug;70(8):4906–4910. doi: 10.1128/AEM.70.8.4906-4910.2004
   PubMed Web of Science ®Google Scholar
• Millar BC, Moore JE. Hospital ice, ice machines, and water as sources of nontuberculous mycobacteria: description of qualitative risk assessment models to determine host-nontuberculous mycobacteria interplay. Int J Mycobacteriol. 2020 Oct;9(4):347–362. doi: 10.4103/ijmy.ijmy_179_20
   PubMed Web of Science ®Google Scholar
• Gira AK, Reisenauer AH, Hammock L, et al. Furunculosis due to Mycobacterium mageritense associated with footbaths at a nail salon. J Clin Microbiol. 2004 Apr;42(4):1813–1817. doi: 10.1128/JCM.42.4.1813-1817.2004
   PubMed Web of Science ®Google Scholar
• Lahiri A, Kneisel J, Kloster I, et al. Abundance of Mycobacterium avium ssp. hominissuis in soil and dust in Germany - implications for the infection route. Lett Appl Microbiol. 2014 Jul;59(1):65–70. doi: 10.1111/lam.12243
   PubMed Web of Science ®Google Scholar
• De Groote MA, Pace NR, Fulton K, et al. Relationships between Mycobacterium isolates from patients with pulmonary mycobacterial infection and potting soils. Appl Environ Microbiol. 2006 Dec;72(12):7602–7606. doi: 10.1128/AEM.00930-06
   PubMed Web of Science ®Google Scholar
• Iivanainen EK, Martikainen PJ, Räisänen ML, et al. Mycobacteria in boreal coniferous forest soils. FEMS Microbiol Ecol. 1997;23(4):325–332. doi: 10.1016/S0168-6496(97)00040-8
   Web of Science ®Google Scholar
• Bouam A, Armstrong N, Levasseur A, et al. Mycobacterium terramassiliense, Mycobacterium rhizamassiliense and Mycobacterium numidiamassiliense sp. nov., three new Mycobacterium simiae complex species cultured from plant roots. Sci Rep. 2018 Jun 18;8(1):9309. doi: 10.1038/s41598-018-27629-1
   PubMedGoogle Scholar
• Tran PM, Dahl JL. Mycobacterium sarraceniae sp. nov. And Mycobacterium helvum sp. nov., isolated from the pitcher plant Sarracenia purpurea. Int J Syst Evol Microbiol. 2016 Nov;66(11):4480–4485. doi: 10.1099/ijsem.0.001377
   PubMedGoogle Scholar
• Primm TP, Lucero CA, Falkinham JO. 3rd. Health impacts of environmental mycobacteria. Clin Microbiol Rev. 2004 Jan;17(1):98–106. doi: 10.1128/CMR.17.1.98-106.2004
   PubMed Web of Science ®Google Scholar
• Mangione EJ, Huitt G, Lenaway D, et al. Nontuberculous mycobacterial disease following hot tub exposure. Emerg Infect Dis. 2001 Nov;7(6):1039–1042. doi: 10.3201/eid0706.010623
   PubMed Web of Science ®Google Scholar
• Choi S, Choi MI. Solation of nontuberculous mycobacteria (NTM) from air conditioner dust. Korean J Clin Lab Sci. 2017;49:435–438. doi: 10.15324/kjcls.2017.49.4.435
   Google Scholar
• Leski TA, Malanoski AP, Gregory MJ, et al. Application of a broad-range resequencing array for detection of pathogens in desert dust samples from Kuwait and Iraq. Appl Environ Microbiol. 2011 Jul;77(13):4285–4292. doi: 10.1128/AEM.00021-11
   PubMed Web of Science ®Google Scholar
• Parikh A, Vinnard C, Fahrenfeld N, et al. Revisiting John snow to meet the challenge of nontuberculous mycobacterial lung disease. Int J Environ Res Public Health. 2019 Nov 1;16(21):4250. doi: 10.3390/ijerph16214250
   PubMed Web of Science ®Google Scholar
• Pyarali FF, Schweitzer M, Bagley V, et al. Increasing non-tuberculous mycobacteria infections in veterans with COPD and association with increased risk of mortality. Front Med. 2018;5:311. doi: 10.3389/fmed.2018.00311
   Web of Science ®Google Scholar
• Jankovic M, Samarzija M, Sabol I, et al. Geographical distribution and clinical relevance of non-tuberculous mycobacteria in Croatia. Int J Tuberc Lung Dis. 2013 Jun;17(6):836–841. doi: 10.5588/ijtld.12.0843
   PubMed Web of Science ®Google Scholar
• Liu CF, Song YM, He WC, et al. Nontuberculous mycobacteria in China: incidence and antimicrobial resistance spectrum from a nationwide survey. Infect Dis Poverty. 2021 Apr 29;10(1):59. doi: 10.1186/s40249-021-00844-1
   PubMed Web of Science ®Google Scholar
• Adjemian J, Olivier KN, Seitz AE, et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012 Apr 15;185(8):881–886. doi: 10.1164/rccm.201111-2016OC
   PubMed Web of Science ®Google Scholar
• Strollo SE, Adjemian J, Adjemian MK, et al. The burden of pulmonary nontuberculous mycobacterial disease in the United states. Ann Am Thorac Soc. 2015 Oct;12(10):1458–1464. doi: 10.1513/AnnalsATS.201503-173OC
   PubMed Web of Science ®Google Scholar
• Adjemian J, Olivier KN, Seitz AE, et al. Spatial clusters of nontuberculous mycobacterial lung disease in the United states. Am J Respir Crit Care Med. 2012 Sep 15;186(6):553–558. doi: 10.1164/rccm.201205-0913OC
   PubMed Web of Science ®Google Scholar
• Maki T, Noda J, Morimoto K, et al. Long-range transport of airborne bacteria over East Asia: Asian dust events carry potentially nontuberculous Mycobacterium populations. Environ Int. 2022 Oct;168:107471
   PubMed Web of Science ®Google Scholar
• Thomson RM, Furuya-Kanamori L, Coffey C, et al. Influence of climate variables on the rising incidence of nontuberculous mycobacterial (NTM) infections in Queensland, Australia 2001-2016. Sci Total Environ. 2020 Oct 20;740:139796. doi: 10.1016/j.scitotenv.2020.139796
   PubMed Web of Science ®Google Scholar
• Honda JR, Bernhard JN, Chan ED. Natural disasters and nontuberculous mycobacteria: a recipe for increased disease? Chest. 2015 Feb;147(2):304–308. doi: 10.1378/chest.14-0974
   PubMed Web of Science ®Google Scholar
• Kambali S, Quinonez E, Sharifi A, et al. Pulmonary nontuberculous mycobacterial disease in Florida and association with large-scale natural disasters. BMC Public Health. 2021 Nov 10;21(1):2058. doi: 10.1186/s12889-021-12115-7
   PubMed Web of Science ®Google Scholar
• Nishiuchi Y, Iwamoto T, Maruyama F. Infection sources of a common non-tuberculous mycobacterial Pathogen, Mycobacterium avium complex. Front Med. 2017;4:27. doi: 10.3389/fmed.2017.00027
   PubMed Web of Science ®Google Scholar
• Jeon D. Infection source and epidemiology of nontuberculous mycobacterial lung disease. Tuberc Respir Dis (Seoul). 2019 Apr;82(2):94–101. doi: 10.4046/trd.2018.0026
   PubMed Web of Science ®Google Scholar
• Park Y, Kwak SH, Yong SH, et al. The association between behavioral risk factors and nontuberculous mycobacterial pulmonary disease. Yonsei Med J. 2021 Aug;62(8):702–707. doi: 10.3349/ymj.2021.62.8.702
   PubMed Web of Science ®Google Scholar
• Gundacker ND, Gonzalez JA, Sheinin YM, et al. Hot tub lung: case report and review of the literature. WMJ. 2022 Jul;121(2):E31–E33.
   PubMedGoogle Scholar
• Campos-Gutierrez S, Ramos-Real MJ, Abreu R, et al. Pseudo-outbreak of Mycobacterium fortuitum in a hospital bronchoscopy unit. Am J Infect Control. 2020 Jul;48(7):765–769. doi: 10.1016/j.ajic.2019.11.019
   PubMed Web of Science ®Google Scholar
• Falkinham JO. Growth in catheter biofilms and antibiotic resistance of Mycobacterium avium. J Med Microbiol. 2007 Feb;56(Pt 2):250–254. doi: 10.1099/jmm.0.46935-0
   PubMed Web of Science ®Google Scholar
• Motawea KR, Rabea RK, Elhalag RH, et al. Cosmetic operative care abroad leads to a multidrug-resistant Mycobacterium abscessus infection in a patient: a case report. J Med Case Rep. 2022 Nov 29;16(1):448. doi: 10.1186/s13256-022-03678-z
   PubMedGoogle Scholar
• Bolcato M, Rodriguez D, Aprile A. Risk management in the New frontier of professional liability for nosocomial infection: review of the literature on mycobacterium chimaera. Int J Environ Res Public Health. 2020 Oct 7;17(19):7328. doi: 10.3390/ijerph17197328
   PubMed Web of Science ®Google Scholar
• Aitken ML, Limaye A, Pottinger P, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med. 2012 Jan 15;185(2):231–232. doi: 10.1164/ajrccm.185.2.231
   PubMed Web of Science ®Google Scholar
• Chan ED, Iseman MD. Underlying host risk factors for nontuberculous mycobacterial lung disease. Semin Respir Crit Care Med. 2013 Feb;34(1):110–123. doi: 10.1055/s-0033-1333573
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Marras TK, Adjemian J, et al. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. Managed Care health plan, 2008-2015. Ann Am Thorac Soc. 2020 Feb;17(2):178–185. doi: 10.1513/AnnalsATS.201804-236OC
   PubMed Web of Science ®Google Scholar
• Loebinger MR, Quint JK, van der Laan R, et al. Risk factors for nontuberculous mycobacterial pulmonary disease: a systematic literature review and meta-analysis. Chest. 2023 Jun 17;164(5):1115–1124. doi: 10.1016/j.chest.2023.06.014
   PubMed Web of Science ®Google Scholar
• Prieto MD, Alam ME, Franciosi AN, et al. Global burden of nontuberculous mycobacteria in the cystic fibrosis population: a systematic review and meta-analysis. ERJ Open Res. 2023 Jan;9(1):00336–2022. doi: 10.1183/23120541.00336-2022
   PubMedGoogle Scholar
• Low D, Wilson DA, Flume PA. Screening practices for nontuberculous mycobacteria at US cystic fibrosis centers. J Cyst Fibros. 2020 Jul;19(4):569–574. doi: 10.1016/j.jcf.2020.02.013
   PubMed Web of Science ®Google Scholar
• Esther CR Jr., Esserman DA, Gilligan P, et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros. 2010 Mar;9(2):117–123. doi: 10.1016/j.jcf.2009.12.001
   PubMed Web of Science ®Google Scholar
• Qvist T, Taylor-Robinson D, Waldmann E, et al. Comparing the harmful effects of nontuberculous mycobacteria and gram negative bacteria on lung function in patients with cystic fibrosis. J Cyst Fibros. 2016 May;15(3):380–385. doi: 10.1016/j.jcf.2015.09.007
   PubMed Web of Science ®Google Scholar
• Eikani MS, Nugent M, Poursina A, et al. Clinical course and significance of nontuberculous mycobacteria and its subtypes in cystic fibrosis. BMC Infect Dis. 2018 Jul 6;18(1):311. doi: 10.1186/s12879-018-3200-z
   PubMedGoogle Scholar
• Marras TK, Campitelli MA, Kwong JC, et al. Risk of nontuberculous mycobacterial pulmonary disease with obstructive lung disease. Eur Respir J. 2016 Sep;48(3):928–931. doi: 10.1183/13993003.00033-2016
   PubMed Web of Science ®Google Scholar
• Andrejak C, Nielsen R, Thomsen VO, et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013 Mar;68(3):256–262. doi: 10.1136/thoraxjnl-2012-201772
   PubMed Web of Science ®Google Scholar
• Shu CC, Wei YF, Chen KH, et al. Inhaled corticosteroids increase risk of nontuberculous mycobacterial lung disease: a nested case-control study and meta-analysis. J Infect Dis. 2022 Feb 15;225(4):627–636. doi: 10.1093/infdis/jiab428
   PubMed Web of Science ®Google Scholar
• Huang CT, Tsai YJ, Wu HD, et al. Impact of non-tuberculous mycobacteria on pulmonary function decline in chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2012 Apr;16(4):539–545. doi: 10.5588/ijtld.11.0412
   PubMed Web of Science ®Google Scholar
• Chu H, Zhao L, Xiao H, et al. Prevalence of nontuberculous mycobacteria in patients with bronchiectasis: a meta-analysis. Arch Med Sci. 2014 Aug 29;10(4):661–668. doi: 10.5114/aoms.2014.44857
   PubMed Web of Science ®Google Scholar
• Zhou Y, Mu W, Zhang J, et al. Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006-2021: a systematic review and meta-analysis. BMJ Open. 2022 Aug 1;12(8):e055672. doi: 10.1136/bmjopen-2021-055672
   PubMed Web of Science ®Google Scholar
• Mirsaeidi M, Hadid W, Ericsoussi B, et al. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int J Infect Dis. 2013 Nov;17(11):e1000–4. doi: 10.1016/j.ijid.2013.03.018
   PubMed Web of Science ®Google Scholar
• Aksamit TR, O’Donnell AE, Barker A, et al. Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. Chest. 2017 May;151(5):982–992. doi: 10.1016/j.chest.2016.10.055
   PubMed Web of Science ®Google Scholar
• Yin H, Gu X, Wang Y, et al. Clinical characteristics of patients with bronchiectasis with nontuberculous mycobacterial disease in Mainland China: a single center cross-sectional study. BMC Infect Dis. 2021 Dec 6;21(1):1216. doi: 10.1186/s12879-021-06917-8
   PubMed Web of Science ®Google Scholar
• Lin CY, Huang HY, Hsieh MH, et al. Impacts of Nontuberculous Mycobacteria Isolates in Non-cystic Fibrosis Bronchiectasis: A 16-Year Cohort Study in Taiwan. Front Microbiol. 2022;13:868435. doi: 10.3389/fmicb.2022.868435
   PubMed Web of Science ®Google Scholar
• Wang PH, Pan SW, Wang SM, et al. The Impact of nontuberculous mycobacteria species on mortality in patients with nontuberculous mycobacterial lung disease. Front Microbiol. 2022;13:909274. doi: 10.3389/fmicb.2022.909274
   PubMed Web of Science ®Google Scholar
• Huang HL, Cheng MH, Lu PL, et al. Epidemiology and predictors of NTM pulmonary infection in Taiwan - a retrospective, five-year multicenter study. Sci Rep. 2017 Nov 24;7(1):16300. doi: 10.1038/s41598-017-16559-z
   PubMedGoogle Scholar
• Fifor A, Krukowski K, Honda JR. Sex, ancestry, senescence, and aging (SAnSA) are stark drivers of nontuberculous mycobacterial pulmonary disease. J Clin Tuberc Other Mycobact Dis. 2022 Feb;26:100297. doi: 10.1016/j.jctube.2022.100297
   PubMedGoogle Scholar
• Namasivayam S, Sher A, Glickman MS, et al. The microbiome and tuberculosis: early evidence for cross talk. MBio. 2018 Sep 18;9(5). doi: 10.1128/mBio.01420-18
   PubMed Web of Science ®Google Scholar
• Thornton CS, Mellett M, Jarand J, et al. The respiratory microbiome and nontuberculous mycobacteria: an emerging concern in human health. Eur Respir Rev. 2021 Jun 30;30(160):200299. doi: 10.1183/16000617.0299-2020
   PubMed Web of Science ®Google Scholar
• Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010 Oct 1;182(7):970–976. doi: 10.1164/rccm.201002-0310OC
   PubMed Web of Science ®Google Scholar
• Thomson RM. Centre NTMwgaQTC, Queensland mycobacterial reference L. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis. 2010 Oct;16(10):1576–1583. doi: 10.3201/eid1610.091201
   PubMed Web of Science ®Google Scholar
• Park Y, Kim CY, Park MS, et al. Age- and sex-related characteristics of the increasing trend of nontuberculous mycobacteria pulmonary disease in a tertiary hospital in South Korea from 2006 to 2016. Korean J Intern Med. 2020 Nov;35(6):1424–1431. doi: 10.3904/kjim.2019.395
   PubMed Web of Science ®Google Scholar
• Cassidy PM, Hedberg K, Saulson A, et al. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis. 2009 Dec 15;49(12):e124–9. doi: 10.1086/648443
   PubMed Web of Science ®Google Scholar
• Izumi K, Morimoto K, Hasegawa N, et al. Epidemiology of adults and children treated for nontuberculous mycobacterial pulmonary disease in Japan. Ann Am Thorac Soc. 2019 Mar;16(3):341–347. doi: 10.1513/AnnalsATS.201806-366OC
   PubMed Web of Science ®Google Scholar
• Sexton P, Harrison AC. Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J. 2008 Jun;31(6):1322–1333. doi: 10.1183/09031936.00140007
   PubMed Web of Science ®Google Scholar
• Colombo RE, Hill SC, Claypool RJ, et al. Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest. 2010 Mar;137(3):629–634. doi: 10.1378/chest.09-1173
   PubMed Web of Science ®Google Scholar
• Kobashi Y, Yoshida K, Niki Y, et al. Sibling cases of Mycobacterium avium complex disease associated with hematological disease. J Infect Chemother. 2006 Oct;12(5):331–334. doi: 10.1007/s10156-006-0461-Z
   PubMedGoogle Scholar
• Adjemian J, Frankland TB, Daida YG, et al. Epidemiology of Nontuberculous Mycobacterial Lung Disease and Tuberculosis, Hawaii, USA. Emerg Infect Dis. 2017 Mar;23(3):439–447. doi: 10.3201/eid2303.161827
   PubMed Web of Science ®Google Scholar
• Blakney RA, Ricotta EE, Frankland TB, et al. Incidence of Nontuberculous Mycobacterial Pulmonary Infection, by Ethnic Group, Hawaii, USA, 2005-2019. Emerg Infect Dis. 2022 Aug;28(8):1543–1550. doi: 10.3201/eid2808.212375
   PubMed Web of Science ®Google Scholar
• Schildkraut JA, Gallagher J, Morimoto K, et al. Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation. Respir med. 2020 Nov;173:106164
   PubMed Web of Science ®Google Scholar
• van Ingen J, Obradovic M, Hassan M, et al. Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex - disease burden, unmet needs, and advances in treatment developments. Expert Rev Respir Med. 2021 Nov;15(11):1387–1401. doi: 10.1080/17476348.2021.1987891
   PubMed Web of Science ®Google Scholar
• Oliveira MJ, Gaio AR, Gomes M, et al. Mycobacterium avium infection in Portugal. Int J Tuberc Lung Dis. 2017 Feb 1;21(2):218–222. doi: 10.5588/ijtld.16.0002
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Henkle E, Walker A, et al. On the reportability of nontuberculous mycobacterial disease to public health authorities. Ann Am Thorac Soc. 2017 Mar;14(3):314–317. doi: 10.1513/AnnalsATS.201610-802PS
   PubMed Web of Science ®Google Scholar
• Adjemian J, Daniel-Wayman S, Ricotta E, et al. Epidemiology of nontuberculous mycobacteriosis. Semin Respir Crit Care Med. 2018 Jun;39(3):325–335. doi: 10.1055/s-0038-1651491
   PubMed Web of Science ®Google Scholar
• Dahl VN, Molhave M, Floe A, et al. Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review. Int J Infect Dis. 2022 Dec;125:120–131. doi: 10.1016/j.ijid.2022.10.013
   PubMed Web of Science ®Google Scholar
• Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017 Nov;72(Suppl 2):ii1–ii64. doi: 10.1136/thoraxjnl-2017-210927
   PubMed Web of Science ®Google Scholar
• Ahmed I, Tiberi S, Farooqi J, et al. Non-tuberculous mycobacterial infections-A neglected and emerging problem. Int J Infect Dis. 2020 Mar;92S:S46–S50
   PubMedGoogle Scholar
• Hoefsloot W, van Ingen J, Andrejak C, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013 Dec;42(6):1604–1613. doi: 10.1183/09031936.00149212
   PubMed Web of Science ®Google Scholar
• Tsai YV, Derrick C, Yunusa I, et al. Epidemiology, outcomes and tolerability of protracted treatment of nontuberculous mycobacterial infections at a community teaching hospital in the southeastern United states. Antibiotics. 2022 Nov 29;11(12):1720. doi: 10.3390/antibiotics11121720
   Google Scholar
• Zweijpfenning SMH, van Ingen J, Hoefsloot W. Geographic distribution of nontuberculous mycobacteria isolated from clinical specimens: asystematic review. Semin Respir Crit Care Med. 2018 Jun;39(3):336–342. doi: 10.1055/s-0038-1660864
   PubMed Web of Science ®Google Scholar
• Dahl VN, Laursen LL, He Y, et al. Species distribution among patients with nontuberculous mycobacteria pulmonary disease in Europe. J Infect. 2023 Nov;87(5):469–472. doi: 10.1016/j.jinf.2023.03.010
   PubMed Web of Science ®Google Scholar
• Lee YM, Kim MJ, Kim YJ. Increasing trend of nontuberculous mycobacteria isolation in a referral clinical laboratory in South Korea. Medicina (Kaunas). 2021 Jul 16;57(7):720. doi: 10.3390/medicina57070720
   PubMed Web of Science ®Google Scholar
• Ryoo SW, Shin S, Shim MS, et al. Spread of nontuberculous mycobacteria from 1993 to 2006 in Koreans. J Clin Lab Anal. 2008;22(6):415–420. doi: 10.1002/jcla.20278
   PubMed Web of Science ®Google Scholar
• Okoi C, Anderson STB, Antonio M, et al. Non-tuberculous mycobacteria isolated from pulmonary samples in sub-Saharan Africa - a systematic review and meta analyses. Sci Rep. 2017 Sep 20;7(1):12002. doi: 10.1038/s41598-017-12175-z
   PubMedGoogle Scholar
• Cheng A, Sun HY, Tsai YT, et al. Longitudinal non-cystic fibrosis trends of pulmonary Mycobacterium abscessus disease from 2010 to 2017: spread of the “globally successful clone” in Asia. ERJ Open Res. 2021 Jan;7(1):00191–2020. doi: 10.1183/23120541.00191-2020
   PubMedGoogle Scholar
• Donohue MJ, Wymer L. Increasing prevalence rate of nontuberculous mycobacteria infections in Five states, 2008-2013. Ann Am Thorac Soc. 2016 Dec;13(12):2143–2150. doi: 10.1513/AnnalsATS.201605-353OC
   PubMed Web of Science ®Google Scholar
• Boyle DP, Zembower TR, Reddy S, et al. Comparison of Clinical Features, Virulence, and Relapse among Mycobacterium avium Complex Species. Am J Respir Crit Care Med. 2015 Jun 1;191(11):1310–1317. doi: 10.1164/rccm.201501-0067OC
   PubMed Web of Science ®Google Scholar
• Dean SG, Ricotta EE, Fintzi J, et al. Mycobacterial testing trends, United states, 2009-2015(1). Emerg Infect Dis. 2020 Sep;26(9):2243–2246. doi: 10.3201/eid2609.200749
   PubMed Web of Science ®Google Scholar
• Marras TK, Mendelson D, Marchand-Austin A, et al. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis. 2013 Nov;19(11):1889–1891. doi: 10.3201/eid1911.130737
   PubMed Web of Science ®Google Scholar
• Santin M, Barrabeig I, Malchair P, et al. Pulmonary infections with nontuberculous mycobacteria, Catalonia, Spain, 1994-2014. Emerg Infect Dis. 2018 Jun;24(6):1091–1094. doi: 10.3201/eid2406.172095
   PubMed Web of Science ®Google Scholar
• Ringshausen FC, Wagner D, de Roux A, et al. Prevalence of nontuberculous mycobacterial pulmonary disease, Germany, 2009-2014. Emerg Infect Dis. 2016 Jun;22(6):1102–1105. doi: 10.3201/eid2206.151642
   PubMed Web of Science ®Google Scholar
• Henry MT, Inamdar L, O’Riordain D, et al. Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur Respir J. 2004 May;23(5):741–746. doi: 10.1183/09031936.04.00114004
   PubMed Web of Science ®Google Scholar
• Moore JE, Kruijshaar ME, Ormerod LP, et al. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. BMC Public Health. 2010 Oct 15;10(1):612. doi: 10.1186/1471-2458-10-612
   PubMedGoogle Scholar
• Cowman S, Burns K, Benson S, et al. The antimicrobial susceptibility of non-tuberculous mycobacteria. J Infect. 2016 Mar;72(3):324–331. doi: 10.1016/j.jinf.2015.12.007
   PubMed Web of Science ®Google Scholar
• van Ingen J, Hoefsloot W, Dekhuijzen PN, et al. The changing pattern of clinical mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis. 2010 Sep;14(9):1176–1180.
   PubMed Web of Science ®Google Scholar
• Koh WJ, Chang B, Jeong BH, et al. Increasing recovery of nontuberculous mycobacteria from respiratory specimens over a 10-year period in a tertiary referral hospital in South Korea. Tuberc Respir Dis (Seoul). 2013 Nov;75(5):199–204. doi: 10.4046/trd.2013.75.5.199
   PubMedGoogle Scholar
• Ko RE, Moon SM, Ahn S, et al. Changing epidemiology of nontuberculous mycobacterial lung diseases in a tertiary referral hospital in Korea between 2001 and 2015. J Korean Med Sci. 2018 Feb 19;33(8):e65. doi: 10.3346/jkms.2018.33.e65
   PubMed Web of Science ®Google Scholar
• Lee H, Myung W, Koh WJ, et al. Epidemiology of nontuberculous mycobacterial infection, South Korea, 2007-2016. Emerg Infect Dis. 2019 Mar;25(3):569–572. doi: 10.3201/eid2503.181597
   PubMed Web of Science ®Google Scholar
• Park SC, Kang MJ, Han CH, et al. Prevalence, incidence, and mortality of nontuberculous mycobacterial infection in Korea: a nationwide population-based study. BMC Pulm Med. 2019 Aug 1;19(1):140. doi: 10.1186/s12890-019-0901-z
   PubMedGoogle Scholar
• Chien JY, Lai CC, Sheng WH, et al. Pulmonary infection and colonization with nontuberculous mycobacteria, Taiwan, 2000-2012. Emerg Infect Dis. 2014 Aug;20(8):1382–1385. doi: 10.3201/eid2008.131673
   PubMed Web of Science ®Google Scholar
• Ding LW, Lai CC, Lee LN, et al. Disease caused by non-tuberculous mycobacteria in a university hospital in Taiwan, 1997-2003. Epidemiol Infect. 2006 Oct;134(5):1060–1067. doi: 10.1017/S0950268805005698
   PubMed Web of Science ®Google Scholar
• Namkoong H, Kurashima A, Morimoto K, et al. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis. 2016 Jun;22(6):1116–1117. doi: 10.3201/eid2206.151086
   PubMed Web of Science ®Google Scholar
• Kim HO, Lee K, Choi HK, et al. Incidence, comorbidities, and treatment patterns of nontuberculous mycobacterial infection in South Korea. Medicine (Baltimore). 2019 Nov;98(45):e17869. doi: 10.1097/MD.0000000000017869
   PubMed Web of Science ®Google Scholar
• O’Brien DP, Currie BJ, Krause VL. Nontuberculous mycobacterial disease in northern Australia: a case series and review of the literature. Clin Infect Dis. 2000 Oct;31(4):958–967. doi: 10.1086/318136
   PubMed Web of Science ®Google Scholar
• Thomson R, Donnan E, Konstantinos A. Notification of nontuberculous mycobacteria: an Australian perspective. Ann Am Thorac Soc. 2017 Mar;14(3):318–323. doi: 10.1513/AnnalsATS.201612-994OI
   PubMed Web of Science ®Google Scholar
• Chaptal M, Andrejak C, Bonifay T, et al. Epidemiology of infection by pulmonary non-tuberculous mycobacteria in French Guiana 2008-2018. PLoS Negl Trop Dis. 2022 Sep;16(9):e0010693. doi: 10.1371/journal.pntd.0010693
   PubMedGoogle Scholar
• Greif G, Coitinho C, van Ingen J, et al. Species distribution and isolation Frequency of nontuberculous mycobacteria, Uruguay. Emerg Infect Dis. 2020 May;26(5):1014–1018. doi: 10.3201/eid2605.191631
   PubMed Web of Science ®Google Scholar
• Bethencourt Mirabal A, Ferrer G. Lung Nontuberculous Mycobacterial Infections. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
   Google Scholar
• Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020 Jul;56(1):2000535. doi: 10.1183/13993003.00535-2020
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002 Oct;15(4):716–746. doi: 10.1128/CMR.15.4.716-746.2002
   PubMed Web of Science ®Google Scholar
• Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011 Feb 1;183(3):405–410. doi: 10.1164/rccm.201003-0395OC
   PubMed Web of Science ®Google Scholar
• Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med. 2012 Nov 1;186(9):917–925. doi: 10.1164/rccm.201111-2005OC
   PubMed Web of Science ®Google Scholar
• Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006 Sep;6(9):570–581. doi: 10.1016/S1473-3099(06)70578-3
   PubMed Web of Science ®Google Scholar
• Ulukanligil M, Aslan G, Tasci S. A comparative study on the different staining methods and number of specimens for the detection of acid fast bacilli. Mem Inst Oswaldo Cruz. 2000 Nov;95(6):855–858. doi: 10.1590/S0074-02762000000600019
   PubMed Web of Science ®Google Scholar
• Wright PW, Wallace RJ Jr., Wright NW, et al. Sensitivity of fluorochrome microscopy for detection of Mycobacterium tuberculosis versus nontuberculous mycobacteria. J Clin Microbiol. 1998 Apr;36(4):1046–1049. doi: 10.1128/JCM.36.4.1046-1049.1998
   PubMed Web of Science ®Google Scholar
• Murray SJ, Barrett A, Magee JG, et al. Optimisation of acid fast smears for the direct detection of mycobacteria in clinical samples. J Clin Pathol. 2003 Aug;56(8):613–615. doi: 10.1136/jcp.56.8.613
   PubMed Web of Science ®Google Scholar
• Saleeb PG, Drake SK, Murray PR, et al. Identification of mycobacteria in solid-culture media by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2011 May;49(5):1790–1794. doi: 10.1128/JCM.02135-10
   PubMed Web of Science ®Google Scholar
• Lotz A, Ferroni A, Beretti JL, et al. Rapid identification of mycobacterial whole cells in solid and liquid culture media by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2010 Dec;48(12):4481–4486. doi: 10.1128/JCM.01397-10
   PubMed Web of Science ®Google Scholar
• El Khechine A, Couderc C, Flaudrops C, et al. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry identification of mycobacteria in routine clinical practice. PLoS One. 2011;6(9):e24720. doi: 10.1371/journal.pone.0024720
   PubMed Web of Science ®Google Scholar
• Fangous MS, Mougari F, Gouriou S, et al. Classification algorithm for subspecies identification within the Mycobacterium abscessus species, based on matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2014 Sep;52(9):3362–3369. doi: 10.1128/JCM.00788-14
   PubMed Web of Science ®Google Scholar
• Rodriguez-Sanchez B, Ruiz-Serrano MJ, Marin M, et al. Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of nontuberculous mycobacteria from clinical isolates. J Clin Microbiol. 2015 Aug;53(8):2737–2740. doi: 10.1128/JCM.01380-15
   PubMed Web of Science ®Google Scholar
• Huang JH, Kao PN, Adi V, et al. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest. 1999 Apr;115(4):1033–1040. doi: 10.1378/chest.115.4.1033
   PubMed Web of Science ®Google Scholar
• Daley CL, Winthrop KL. Mycobacterium avium complex: addressing gaps in diagnosis and management. J Infect Dis. 2020 Aug 20;222(Suppl 4):S199–S211. doi: 10.1093/infdis/jiaa354
   PubMedGoogle Scholar
• Herrera V, Perry S, Parsonnet J, et al. Clinical application and limitations of interferon-gamma release assays for the diagnosis of latent tuberculosis infection. Clin Infect Dis. 2011 Apr 15;52(8):1031–1037. doi: 10.1093/cid/cir068
   PubMed Web of Science ®Google Scholar
• Hamada Y, Gupta RK, Quartagno M, et al. Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis. EClinicalMedicine. 2023 Feb;56:101815.
   PubMedGoogle Scholar
• Guan CP, Wu YH, Wang XF, et al. The performance of interferon gamma release assays in patients with nontuberculous mycobacterial infection: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2023 Oct;42(10):1251–1262. doi: 10.1007/s10096-023-04662-1
   PubMedGoogle Scholar
• Martinez-Planas A, Baquero-Artigao F, Santiago B, et al. Interferon-gamma release assays differentiate between Mycobacterium avium complex and tuberculous Lymphadenitis in children. J Pediatr. 2021 Sep;236:211–218 e2 doi: 10.1016/j.peds.2021.05.008
   PubMed Web of Science ®Google Scholar
• Yang C, Luo X, Fan L, et al. Performance of interferon-gamma release assays in the diagnosis of nontuberculous mycobacterial diseases-A retrospective survey from 2011 to 2019. Front Cell Infect Microbiol. 2020;10:571230. doi: 10.3389/fcimb.2020.571230
   PubMed Web of Science ®Google Scholar
• Steindor M, Stehling F, Olivier M, et al. Species-specific interferon-gamma release assay for the diagnosis of Mycobacterium abscessus complex infection. Front Microbiol. 2021;12:692395. doi: 10.3389/fmicb.2021.692395
   PubMed Web of Science ®Google Scholar
• Cao XJ, Li YP, Wang JY, et al. MPT64 assays for the rapid detection of Mycobacterium tuberculosis. BMC Infect Dis. 2021 Apr 10;21(1):336. doi: 10.1186/s12879-021-06022-w
   PubMed Web of Science ®Google Scholar
• Yin X, Zheng L, Lin L, et al. Commercial MPT64-based tests for rapid identification of Mycobacterium tuberculosis complex: a meta-analysis. J Infect. 2013 Nov;67(5):369–377. doi: 10.1016/j.jinf.2013.06.009
   PubMed Web of Science ®Google Scholar
• Dadheech M, Malhotra AG, Patel S, et al. Molecular identification of non-tuberculous mycobacteria in suspected tuberculosis cases in central India. Cureus. 2023 Jun;15(6):e39992. doi: 10.7759/cureus.39992
   PubMedGoogle Scholar
• Chen S, Wang F, Xue Y, et al. Doubled nontuberculous mycobacteria isolation as a consequence of changes in the diagnosis algorithm. Infect Drug Resist. 2022;15:3347–3355. doi: 10.2147/IDR.S368671
   PubMed Web of Science ®Google Scholar
• Stavri H, Ulea I, Radu DL, et al. Serodiagnosis of environmental mycobacterial infections. J Microbiol Methods. 2011 Sep;86(3):283–290. doi: 10.1016/j.mimet.2011.05.010
   PubMed Web of Science ®Google Scholar
• Kitada S, Kobayashi K, Ichiyama S, et al. Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med. 2008 Apr 1;177(7):793–797. doi: 10.1164/rccm.200705-771OC
   PubMed Web of Science ®Google Scholar
• Jeong BH, Kim SY, Jeon K, et al. Serodiagnosis of Mycobacterium avium complex and Mycobacterium abscessus complex pulmonary disease by use of IgA antibodies to glycopeptidolipid core antigen. J Clin Microbiol. 2013 Aug;51(8):2747–2749. doi: 10.1128/JCM.00702-13
   PubMed Web of Science ®Google Scholar
• Kitada S, Levin A, Hiserote M, et al. Serodiagnosis of Mycobacterium avium complex pulmonary disease in the USA. Eur Respir J. 2013 Aug;42(2):454–460. doi: 10.1183/09031936.00098212
   PubMed Web of Science ®Google Scholar
• Shu CC, Ato M, Wang JT, et al. Sero-diagnosis of Mycobacterium avium complex lung disease using serum immunoglobulin A antibody against glycopeptidolipid antigen in Taiwan. PLoS One. 2013;8(11):e80473. doi: 10.1371/journal.pone.0080473
   PubMed Web of Science ®Google Scholar
• Kobayashi K. Serodiagnosis of Mycobacterium avium complex disease in humans: translational research from basic mycobacteriology to clinical medicine. Jpn J Infect Dis. 2014;67(5):329–332. doi: 10.7883/yoken.67.329
   PubMed Web of Science ®Google Scholar
• Shibata Y, Horita N, Yamamoto M, et al. Diagnostic test accuracy of anti-glycopeptidolipid-core IgA antibodies for Mycobacterium avium complex pulmonary disease: systematic review and meta-analysis. Sci Rep. 2016 Jul 4;6(1):29325. doi: 10.1038/srep29325
   PubMedGoogle Scholar
• Kitada S, Nishiuchi Y, Hiraga T, et al. Serological test and chest computed tomography findings in patients with Mycobacterium avium complex lung disease. Eur Respir J. 2007 Jun;29(6):1217–1223. doi: 10.1183/09031936.00061806
   PubMed Web of Science ®Google Scholar
• Jhun BW, Kim SY, Park HY, et al. Changes in serum IgA antibody levels against the glycopeptidolipid core antigen during antibiotic treatment of Mycobacterium avium complex lung disease. Jpn J Infect Dis. 2017 Sep 25;70(5):582–585. doi: 10.7883/yoken.JJID.2016.523
   PubMed Web of Science ®Google Scholar
• Kitada S, Maekura R, Yoshimura K, et al. Levels of Antibody against Glycopeptidolipid Core as a Marker for Monitoring Treatment Response in Mycobacterium avium Complex Pulmonary Disease: a Prospective Cohort Study. J Clin Microbiol. 2017 Mar;55(3):884–892. doi: 10.1128/JCM.02010-16
   PubMed Web of Science ®Google Scholar
• Ferroni A, Sermet-Gaudelus I, Le Bourgeois M, et al. Measurement of immunoglobulin G against Mycobacterial antigen A60 in patients with cystic fibrosis and lung infection due to Mycobacterium abscessus. Clin Infect Dis. 2005 Jan 1;40(1):58–66. doi: 10.1086/426442
   PubMed Web of Science ®Google Scholar
• Qvist T, Pressler T, Taylor-Robinson D, et al. Serodiagnosis of Mycobacterium abscessus complex infection in cystic fibrosis. Eur Respir J. 2015 Sep;46(3):707–716. doi: 10.1183/09031936.00011815
   PubMed Web of Science ®Google Scholar
• Tran AC, Halse TA, Escuyer VE, et al. Detection of Mycobacterium avium complex DNA directly in clinical respiratory specimens: opportunities for improved turn-around time and cost savings. Diagn Microbiol Infect Dis. 2014 May;79(1):43–48. doi: 10.1016/j.diagmicrobio.2014.01.019
   PubMed Web of Science ®Google Scholar
• Kim S, Park EM, Kwon OJ, et al. Direct application of the PCR restriction analysis method for identifying NTM species in AFB smear-positive respiratory specimens. Int J Tuberc Lung Dis. 2008 Nov;12(11):1344–1346.
   PubMed Web of Science ®Google Scholar
• Seagar AL, Prendergast C, Emmanuel FX, et al. Evaluation of the GenoType mycobacteria direct assay for the simultaneous detection of the Mycobacterium tuberculosis complex and four atypical mycobacterial species in smear-positive respiratory specimens. J Med Microbiol. 2008 May;57(Pt 5):605–611. doi: 10.1099/jmm.0.47484-0
   PubMed Web of Science ®Google Scholar
• Schildhaus HU, Steindor M, Kolsch B, et al. GenoType CM direct® and VisionArray Myco® for the rapid identification of mycobacteria from clinical specimens. J Clin Med. 2022 Apr 25;11(9):2404. doi: 10.3390/jcm11092404
   PubMed Web of Science ®Google Scholar
• Vinnard C, Mezochow A, Oakland H, et al. Assessing response to therapy for nontuberculous mycobacterial lung disease: Quo Vadis? Front Microbiol. 2018;9:2813. doi: 10.3389/fmicb.2018.02813
   PubMed Web of Science ®Google Scholar
• Kim SY, Koh WJ, Park HY, et al. Changes in serum immunomolecules during antibiotic therapy for Mycobacterium avium complex lung disease. Clin Exp Immunol. 2014 Apr;176(1):93–101. doi: 10.1111/cei.12253
   PubMed Web of Science ®Google Scholar
• Hong JY, Jang SH, Kim SY, et al. Elevated serum CA 19-9 levels in patients with pulmonary nontuberculous mycobacterial disease. Braz J Infect Dis. 2016 Jan;20(1):26–32. doi: 10.1016/j.bjid.2015.09.005
   PubMed Web of Science ®Google Scholar
• Lange C, Bottger EC, Cambau E, et al. Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infect Dis. 2022 Jul;22(7):e178–e190. doi: 10.1016/S1473-3099(21)00586-7
   PubMed Web of Science ®Google Scholar
• Kim JY, Lee HW, Yim JJ, et al. Outcomes of adjunctive surgery in patients with nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis. Chest. 2023 Apr;163(4):763–777. doi: 10.1016/j.chest.2022.09.037
   PubMed Web of Science ®Google Scholar
• Kwak N, Whang J, Yang JS, et al. Minimal Inhibitory Concentration of Clofazimine among clinical isolates of nontuberculous mycobacteria and its Impact on treatment outcome. Chest. 2021 Feb;159(2):517–523. doi: 10.1016/j.chest.2020.07.040
   PubMed Web of Science ®Google Scholar
• Jarand J, Davis JP, Cowie RL, et al. Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin. Chest. 2016 May;149(5):1285–1293. doi: 10.1378/chest.15-0543
   PubMed Web of Science ®Google Scholar
• Yang B, Jhun BW, Moon SM, et al. Clofazimine-containing regimen for the treatment of Mycobacterium abscessus lung disease. Antimicrob Agents Chemother. 2017 Jun;61(6). doi: 10.1128/AAC.02052-16
   Web of Science ®Google Scholar
• Pfaeffle HOI, Alameer RM, Marshall MH, et al. Clofazimine for treatment of multidrug-resistant non-tuberculous mycobacteria. Pulm Pharmacol Ther. 2021 Oct;70:102058
   PubMed Web of Science ®Google Scholar
• Opal S, File TM, van der Poll T, et al. An integrated safety Summary of Omadacycline, a novel aminomethylcycline antibiotic. Clin Infect Dis. 2019 Aug 1;69(Suppl 1):S40–S47. doi: 10.1093/cid/ciz398
   PubMedGoogle Scholar
• Shoen C, Benaroch D, Sklaney M, et al. In vitro activities of Omadacycline against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2019 May;63(5). doi: 10.1128/AAC.02522-18
   PubMed Web of Science ®Google Scholar
• Kaushik A, Ammerman NC, Martins O, et al. In vitro activity of New tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2019 Jun;63(6). doi: 10.1128/AAC.00470-19
   Web of Science ®Google Scholar
• Brown-Elliott BA, Wallace RJ Jr. In Vitro Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01947-20
   Web of Science ®Google Scholar
• DeStefano MS, Shoen CM, Alley MRK, et al. In vitro Activities of Epetraborole, a novel bacterial Leucyl-tRNA Synthetase inhibitor, against Mycobacterium avium complex isolates [poster 1713]. (WA) DC: IDWeek; 2022.
   Google Scholar
• Ganapathy US, Gengenbacher M, Dick T. Epetraborole Is Active against Mycobacterium abscessus. Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0115621. doi: 10.1128/AAC.01156-21
   PubMed Web of Science ®Google Scholar
• Locher CP, Jones SM, Hanzelka BL, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. Antimicrob Agents Chemother. 2015 Mar;59(3):1455–1465. doi: 10.1128/AAC.04347-14
   PubMed Web of Science ®Google Scholar
• Grossman TH, Bartels DJ, Mullin S, et al. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother. 2007 Feb;51(2):657–666. doi: 10.1128/AAC.00596-06
   PubMed Web of Science ®Google Scholar
• Durcik M, Tomasic T, Zidar N, et al. ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents. Expert Opin Ther Pat. 2019 Mar;29(3):171–180. doi: 10.1080/13543776.2019.1575362
   PubMed Web of Science ®Google Scholar
• Henderson SR, Stevenson CEM, Malone B, et al. Structural and mechanistic analysis of ATPase inhibitors targeting mycobacterial DNA gyrase. J Antimicrob Chemother. 2020 Oct 1;75(10):2835–2842. doi: 10.1093/jac/dkaa286
   PubMed Web of Science ®Google Scholar
• Cotroneo N, Stokes SS, Pucci MJ, et al. Efficacy of SPR720 in murine models of nontuberculous mycobacterial pulmonary infection. J Antimicrob Chemother. 2023.
   Google Scholar
• Rubio A, Stapleton M, Verma D, et al. Potent activity of a novel gyrase inhibitor (SPR719/SPR720) in vitro and in a prolonged acute Mycobacterium abscessus mouse model of infection [poster SUN-539]. (WA) DC2018: ASM Microbe/American Society for Microbiology; 2018.
   Google Scholar
• Egelund EF, Fennelly KP, Peloquin CA. Medications and monitoring in nontuberculous mycobacteria infections. Clin Chest Med. 2015 Mar;36(1):55–66. doi: 10.1016/j.ccm.2014.11.001
   PubMed Web of Science ®Google Scholar
• Abate G, Stapleton JT, Rouphael N, et al. Variability in the management of adults with pulmonary nontuberculous mycobacterial disease. Clin Infect Dis. 2021 Apr 8;72(7):1127–1137. doi: 10.1093/cid/ciaa252
   PubMed Web of Science ®Google Scholar
• Marras TK, Vinnard C, Zhang Q, et al. Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population. Respir med. 2018 Dec;145:80–88. doi: 10.1016/j.rmed.2018.10.022
   PubMed Web of Science ®Google Scholar
• Mirsaeidi M, Machado RF, Garcia JG, et al. Nontuberculous mycobacterial disease mortality in the United states, 1999-2010: a population-based comparative study. PLoS One. 2014;9(3):e91879. doi: 10.1371/journal.pone.0091879
   PubMed Web of Science ®Google Scholar
• Kwak N, Park J, Kim E, et al. Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and meta-analysis. Clin Infect Dis. 2017 Oct 1;65(7):1077–1084. doi: 10.1093/cid/cix517
   PubMed Web of Science ®Google Scholar
• Diel R, Lipman M, Hoefsloot W. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. BMC Infect Dis. 2018 May 3;18(1):206. doi: 10.1186/s12879-018-3113-x
   PubMedGoogle Scholar
• Im Y, Hwang NY, Kim K, et al. Impact of time between diagnosis and treatment for nontuberculous mycobacterial pulmonary disease on culture conversion and all-cause mortality. Chest. 2022 May;161(5):1192–1200. doi: 10.1016/j.chest.2021.10.048
   PubMed Web of Science ®Google Scholar
• Park Y, Lee EH, Jung I, et al. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis. Respir Res. 2019 Dec 18;20(1):286. doi: 10.1186/s12931-019-1258-9
   PubMed Web of Science ®Google Scholar
• Adjemian J, Prevots DR, Gallagher J, et al. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc. 2014 Jan;11(1):9–16. doi: 10.1513/AnnalsATS.201304-085OC
   PubMedGoogle Scholar
• Izumi K, Morimoto K, Uchimura K, et al. Population-based survey of antimycobacterial drug use among patients with non-tuberculosis mycobacterial pulmonary disease. ERJ Open Res. 2020;6(1):00097–2019. doi: 10.1183/23120541.00097-2019
   PubMedGoogle Scholar
• Ku JH, Henkle E, Aksamit TR, et al. Treatment of nontuberculous mycobacterial (NTM) pulmonary infection in the US bronchiectasis and NTM registry: treatment patterns, adverse events, and adherence to american thoracic Society/Infectious disease Society of America treatment guidelines. Clin Infect Dis. 2023 Jan 13;76(2):338–341. doi: 10.1093/cid/ciac788
   PubMed Web of Science ®Google Scholar
• Kwak N, Lee JH, Kim HJ, et al. New-onset nontuberculous mycobacterial pulmonary disease in bronchiectasis: tracking the clinical and radiographic changes. BMC Pulm Med. 2020 Nov 10;20(1):293. doi: 10.1186/s12890-020-01331-3
   PubMed Web of Science ®Google Scholar
• Kwak N, Kim SA, Choi SM, et al. Longitudinal changes in health-related quality of life according to clinical course among patients with non-tuberculous mycobacterial pulmonary disease: a prospective cohort study. BMC Pulm Med. 2020 May 7;20(1):126. doi: 10.1186/s12890-020-1165-3
   PubMed Web of Science ®Google Scholar
• Pasipanodya JG, Ogbonna D, Ferro BE, et al. Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence. Antimicrob Agents Chemother. 2017 Nov;61(11). doi: 10.1128/AAC.01206-17
   Web of Science ®Google Scholar
• Miwa S, Shirai M, Toyoshima M, et al. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. Ann Am Thorac Soc. 2014 Jan;11(1):23–29. doi: 10.1513/AnnalsATS.201308-266OC
   PubMedGoogle Scholar
• Diel R, Nienhaus A, Ringshausen FC, et al. Microbiologic outcome of interventions against mycobacterium avium complex pulmonary disease: a systematic review. Chest. 2018 Apr;153(4):888–921. doi: 10.1016/j.chest.2018.01.024
   PubMed Web of Science ®Google Scholar
• Morimoto K, Namkoong H, Hasegawa N, et al. Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases. Ann Am Thorac Soc. 2016 Nov;13(11):1904–1911. doi: 10.1513/AnnalsATS.201604-246OC
   PubMed Web of Science ®Google Scholar
• Cheng LP, Chen SH, Lou H, et al. Factors associated with treatment outcome in patients with nontuberculous mycobacterial pulmonary disease: a large population-based retrospective cohort study in Shanghai. Trop Med Infect Dis. 2022 Feb 15;7(2):27. doi: 10.3390/tropicalmed7020027
   PubMedGoogle Scholar
• Kim BG, Jhun BW, Kim H, et al. Treatment outcomes of Mycobacterium avium complex pulmonary disease according to disease severity. Sci Rep. 2022 Feb 4;12(1):1970. doi: 10.1038/s41598-022-06022-z
   PubMed Web of Science ®Google Scholar
• Koh WJ, Moon SM, Kim SY, et al. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J. 2017 Sep;50(3):1602503. doi: 10.1183/13993003.02503-2016
   PubMed Web of Science ®Google Scholar
• Zweijpfenning S, Kops S, Magis-Escurra C, et al. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort. Respir med. 2017 Oct;131:220–224
   PubMed Web of Science ®Google Scholar
• Kim JY, Kim NY, Jung HW, et al. Old age is associated with worse treatment outcome and frequent adverse drug reaction in Mycobacterium avium complex pulmonary disease. BMC Pulm Med. 2022 Jul 14;22(1):269. doi: 10.1186/s12890-022-02063-2
   PubMed Web of Science ®Google Scholar
• Aliberti S, Sotgiu G, Castellotti P, et al. Real-life evaluation of clinical outcomes in patients undergoing treatment for non-tuberculous mycobacteria lung disease: a ten-year cohort study. Respir med. 2020 Apr;164:105899. doi: 10.1016/j.rmed.2020.105899
   PubMed Web of Science ®Google Scholar
• Kwon YS, Han M, Kwon BS, et al. Discontinuation rates attributed to adverse events and treatment outcomes between clarithromycin and azithromycin in Mycobacterium avium complex lung disease: a propensity score analysis. J Glob Antimicrob Resist. 2020 Sep;22:106–112. doi: 10.1016/j.jgar.2020.01.004
   PubMed Web of Science ®Google Scholar
• Diel R, Ringshausen F, Richter E, et al. Microbiological and clinical outcomes of treating non-Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis. Chest. 2017 Jul;152(1):120–142. doi: 10.1016/j.chest.2017.04.166
   PubMed Web of Science ®Google Scholar
• Lee BY, Kim S, Hong Y, et al. Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2015;59(6):2972–2977. doi: 10.1128/AAC.04577-14
   PubMed Web of Science ®Google Scholar
• Boyle DP, Zembower TR, Qi C. Relapse versus Reinfection of Mycobacterium avium Complex Pulmonary Disease. Patient Characteristics and Macrolide Susceptibility. Ann Am Thorac Soc. 2016 Nov;13(11):1956–1961. doi: 10.1513/AnnalsATS.201605-344BC
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr., Brown-Elliott BA, McNulty S, et al. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014 Aug;146(2):276–282. doi: 10.1378/chest.13-2538
   PubMed Web of Science ®Google Scholar
• Kwon YS, Kwon BS, Kim OH, et al. Treatment outcomes after discontinuation of ethambutol due to adverse events in Mycobacterium avium complex lung disease. J Korean Med Sci. 2020 Mar 9;35(9):e59. doi: 10.3346/jkms.2020.35.e59
   PubMed Web of Science ®Google Scholar
• Balavoine C, Blanc F-X, Lanotte P, et al. Adverse events during treatment of nontuberculous mycobacterial lung disease: do they really matter? Eur Respir J. 2018;52(suppl 62):PA2664. doi: 10.1183/13993003.congress-2018.PA2664
   Google Scholar
• Griffith DE, Brown BA, Girard WM, et al. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis. 1995 Sep;21(3):594–598. doi: 10.1093/clinids/21.3.594
   PubMed Web of Science ®Google Scholar
• Costa C, Abeijon P, Rodrigues DA, et al. Factors associated with underreporting of adverse drug reactions by patients: a systematic review. Int J Clin Pharm. 2023 May 29. doi: 10.1007/s11096-023-01592-y
   Web of Science ®Google Scholar
• Garcia-Abeijon P, Costa C, Taracido M, et al. Factors associated with underreporting of adverse drug reactions by health Care professionals: a systematic review update. Drug Saf. 2023 Jul;46(7):625–636. doi: 10.1007/s40264-023-01302-7
   PubMed Web of Science ®Google Scholar
• Brown BA, Griffith DE, Girard W, et al. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin Infect Dis. 1997 May;24(5):958–964. doi: 10.1093/clinids/24.5.958
   PubMed Web of Science ®Google Scholar
• van Ingen J, Aliberti S, Andrejak C, et al. Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey. Clin Infect Dis. 2021 Jul 1;73(1):e256–e259. doi: 10.1093/cid/ciaa1361
   PubMed Web of Science ®Google Scholar
• Kamii Y, Nagai H, Kawashima M, et al. Adverse reactions associated with long-term drug administration in Mycobacterium avium complex lung disease. Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1505–1510. doi: 10.5588/ijtld.18.0171
   PubMed Web of Science ®Google Scholar
• Griffith DE, Eagle G, Thomson R, et al. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559–1569. doi: 10.1164/rccm.201807-1318OC
   PubMed Web of Science ®Google Scholar
• Pravosud V, Mannino DM, Prieto D, et al. Symptom burden and medication use among patients with nontuberculous mycobacterial lung disease. Chronic Obstr Pulm Dis. 2021 Apr 27;8(2):243–254. doi: 10.15326/jcopdf.2020.0184
   PubMed Web of Science ®Google Scholar
• Kim SY, Jhun BW, Moon SM, et al. Mutations in gyrA and gyrB in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium abscessus Complex Clinical Isolates. Antimicrob Agents Chemother. 2018 Sep;62(9). doi: 10.1128/AAC.00527-18
   Web of Science ®Google Scholar
• Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006 Oct 15;174(8):928–934. doi: 10.1164/rccm.200603-450OC
   PubMed Web of Science ®Google Scholar
• Kadota T, Matsui H, Hirose T, et al. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease. BMC Infect Dis. 2016 Jan 27;16(1):31. doi: 10.1186/s12879-016-1384-7
   PubMedGoogle Scholar
• Moon SM, Park HY, Kim SY, et al. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2016 Nov;60(11):6758–6765. doi: 10.1128/AAC.01240-16
   PubMed Web of Science ®Google Scholar
• van der Laan R, Snabilie A, Obradovic M. Meeting the challenges of NTM-PD from the perspective of the organism and the disease process: innovations in drug development and delivery. Respir Res. 2022 Dec 24;23(1):376. doi: 10.1186/s12931-022-02299-w
   PubMed Web of Science ®Google Scholar
• Saxena S, Spaink HP, Forn-Cuni G. Drug Resistance in Nontuberculous Mycobacteria: Mechanisms and Models. Biology. 2021 Jan 29;10(2):96. doi: 10.3390/biology10020096
   PubMedGoogle Scholar
• Nasiri MJ, Haeili M, Ghazi M, et al. New insights in to the intrinsic and acquired drug resistance mechanisms in mycobacteria. Front Microbiol. 2017;8:681. doi: 10.3389/fmicb.2017.00681
   PubMed Web of Science ®Google Scholar
• Li XZ, Zhang L, Nikaido H. Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother. 2004 Jul;48(7):2415–2423. doi: 10.1128/AAC.48.7.2415-2423.2004
   PubMed Web of Science ®Google Scholar
• Schmalstieg AM, Srivastava S, Belkaya S, et al. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother. 2012 Sep;56(9):4806–4815. doi: 10.1128/AAC.05546-11
   PubMed Web of Science ®Google Scholar
• Machado D, Cannalire R, Santos Costa S, et al. Boosting effect of 2-phenylquinoline efflux inhibitors in combination with macrolides against Mycobacterium smegmatis and Mycobacterium avium. ACS Infect Dis. 2015 Dec 11;1(12):593–603. doi: 10.1021/acsinfecdis.5b00052
   PubMed Web of Science ®Google Scholar
• Duan W, Li X, Ge Y, et al. Mycobacterium tuberculosis Rv1473 is a novel macrolides ABC Efflux Pump regulated by WhiB7. Future Microbiol. 2019 Jan;14(1):47–59. doi: 10.2217/fmb-2018-0207
   PubMed Web of Science ®Google Scholar
• Liu J, Takiff HE, Nikaido H. Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J Bacteriol. 1996 Jul;178(13):3791–3795. doi: 10.1128/jb.178.13.3791-3795.1996
   PubMed Web of Science ®Google Scholar
• Silva PE, Bigi F, Santangelo MP, et al. Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2001 Mar;45(3):800–804. doi: 10.1128/AAC.45.3.800-804.2001
   PubMed Web of Science ®Google Scholar
• De Rossi E, Blokpoel MC, Cantoni R, et al. Molecular cloning and functional analysis of a novel tetracycline resistance determinant, tet(V), from Mycobacterium smegmatis. Antimicrob Agents Chemother. 1998 Aug;42(8):1931–1937. doi: 10.1128/AAC.42.8.1931
   PubMed Web of Science ®Google Scholar
• Ramon-Garcia S, Martin C, Ainsa JA, et al. Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J Antimicrob Chemother. 2006 Feb;57(2):252–259. doi: 10.1093/jac/dki436
   PubMed Web of Science ®Google Scholar
• Hurst-Hess KR, Phelps GA, Wilt LA, et al. Mab2780c, a TetV-like efflux pump, confers high-level spectinomycin resistance in mycobacterium abscessus. Tuberculosis (Edinb). 2023 Jan;138:102295. doi: 10.1016/j.tube.2022.102295
   PubMed Web of Science ®Google Scholar
• Gutierrez AV, Richard M, Roquet-Baneres F, et al. The TetR family transcription factor MAB_2299c regulates the expression of two distinct mmps-mmpl efflux pumps involved in cross-resistance to clofazimine and bedaquiline in Mycobacterium abscessus. Antimicrob Agents Chemother. 2019 Oct;63(10). doi: 10.1128/AAC.01000-19
   Web of Science ®Google Scholar
• Lavollay M, Dubee V, Heym B, et al. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. Clin Microbiol Infect. 2014 May;20(5):O297–300. doi: 10.1111/1469-0691.12405
   PubMed Web of Science ®Google Scholar
• Adjei MD, Heinze TM, Deck J, et al. Acetylation and nitrosation of ciprofloxacin by environmental strains of mycobacteria. Can J Microbiol. 2007 Jan;53(1):144–147. doi: 10.1139/w06-101
   PubMed Web of Science ®Google Scholar
• Ainsa JA, Perez E, Pelicic V, et al. Aminoglycoside 2’-N-acetyltransferase genes are universally present in mycobacteria: characterization of the aac(2’)-Ic gene from Mycobacterium tuberculosis and the aac(2’)-id gene from Mycobacterium smegmatis. Mol Microbiol. 1997 Apr;24(2):431–441. doi: 10.1046/j.1365-2958.1997.3471717.x
   PubMed Web of Science ®Google Scholar
• Ripoll F, Pasek S, Schenowitz C, et al. Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One. 2009 Jun 19;4(6):e5660. doi: 10.1371/journal.pone.0005660
   PubMed Web of Science ®Google Scholar
• Wetzstein N, Kohl TA, Schultze TG, et al. Antimicrobial susceptibility and phylogenetic relations in a german cohort infected with Mycobacterium abscessus. J Clin Microbiol. 2020 Nov 18;58(12). doi: 10.1128/JCM.01813-20
   PubMed Web of Science ®Google Scholar
• Lipworth S, Hough N, Leach L, et al. Whole-genome sequencing for predicting clarithromycin resistance in Mycobacterium abscessus. Antimicrob Agents Chemother. 2019 Jan;63(1). doi: 10.1128/AAC.01204-18
   Web of Science ®Google Scholar
• Rominski A, Roditscheff A, Selchow P, et al. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591. J Antimicrob Chemother. 2017 Feb;72(2):376–384. doi: 10.1093/jac/dkw466
   PubMed Web of Science ®Google Scholar
• Baysarowich J, Koteva K, Hughes DW, et al. Rifamycin antibiotic resistance by ADP-ribosylation: structure and diversity of arr. Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4886–4891. doi: 10.1073/pnas.0711939105
   PubMed Web of Science ®Google Scholar
• Griffith DE, Daley CL. Treatment of Mycobacterium abscessus pulmonary disease. Chest. 2022 Jan;161(1):64–75. doi: 10.1016/j.chest.2021.07.035
   PubMed Web of Science ®Google Scholar
• Luthra S, Rominski A, Sander P. The role of antibiotic-target-modifying and antibiotic-modifying enzymes in Mycobacterium abscessus drug resistance. Front Microbiol. 2018;9:2179. doi: 10.3389/fmicb.2018.02179
   PubMed Web of Science ®Google Scholar
• Nessar R, Cambau E, Reyrat JM, et al. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother. 2012 Apr;67(4):810–818. doi: 10.1093/jac/dkr578
   PubMed Web of Science ®Google Scholar
• Wu ML, Aziz DB, Dartois V, et al. NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018 Aug;23(8):1502–1519. doi: 10.1016/j.drudis.2018.04.001
   PubMed Web of Science ®Google Scholar
• Ruth MM, van Ingen J. New insights in the treatment of nontuberculous mycobacterial pulmonary disease. Future Microbiol. 2017 Oct;12(13):1109–1112. doi: 10.2217/fmb-2017-0144
   PubMed Web of Science ®Google Scholar